These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26111544)

  • 1. A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain.
    Wen W; Sitar S; Lynch SY; He E; Ripa SR
    Expert Opin Pharmacother; 2015; 16(11):1593-606. PubMed ID: 26111544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain.
    Bartoli A; Michna E; He E; Wen W
    Postgrad Med; 2015 Jan; 127(1):5-12. PubMed ID: 25526227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
    Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C
    J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain.
    Taber L; Lynch SY; He E; Ripa SR
    Postgrad Med; 2016 Jan; 128(1):23-33. PubMed ID: 26681111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain.
    Hale ME; Zimmerman TR; Eyal E; Malamut R
    J Opioid Manag; 2015; 11(6):507-18. PubMed ID: 26728648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study.
    Rauck RL; Nalamachu S; Wild JE; Walker GS; Robinson CY; Davis CS; Farr SJ
    Pain Med; 2014 Jun; 15(6):975-85. PubMed ID: 24517082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.
    Kopecky EA; Vaughn B; Lagasse S; O'Connor M
    Drugs Aging; 2017 Aug; 34(8):603-613. PubMed ID: 28600725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain.
    Wen W; Taber L; Lynch SY; He E; Ripa S
    J Opioid Manag; 2015; 11(4):339-56. PubMed ID: 26312961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pain intensity and interference with functioning and well-being in subgroups of patients with chronic pain treated with once-daily hydrocodone tablets.
    Bartoli A; Michna E; He E; Wen W
    J Opioid Manag; 2015; 11(6):519-33. PubMed ID: 26728649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
    Portenoy RK; Messina J; Xie F; Peppin J
    Curr Med Res Opin; 2007 Jan; 23(1):223-33. PubMed ID: 17207304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hysingla® ER, a once-daily, single-entity hydrocodone with abuse-deterrent properties in treating chronic nonmalignant and nonneuropathic pain in patients with osteoarthritis.
    Taber L; Baldridge S; He E; Ripa SR
    Postgrad Med; 2017 Jan; 129(1):133-139. PubMed ID: 27983881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of moderate or severe acute low back pain.
    Palangio M; Morris E; Doyle RT; Dornseif BE; Valente TJ
    Clin Ther; 2002 Jan; 24(1):87-99. PubMed ID: 11833838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability of Biphasic-Release Hydrocodone Bitartrate/Acetaminophen Tablets (MNK-155): A Phase III, Multicenter, Open-Label Study in Patients With Osteoarthritis or Chronic Low Back Pain.
    Zheng Y; Kostenbader K; Barrett T; Hisaw E; Giuliani MJ; Chen Y; Young JL
    Clin Ther; 2015 Jun; 37(6):1235-47. PubMed ID: 25913923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential.
    Hale ME; Ma Y; Malamut R
    J Opioid Manag; 2016; 12(2):139-47. PubMed ID: 27194199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Ototoxicity Potential of Once-Daily, Single-Entity Hydrocodone in Patients with Chronic Pain: Results of Two Phase-3 Clinical Studies.
    Campbell K; Kutz JW; Shoup A; Wen W; Lynch SY; He E; Ripa SR
    Pain Physician; 2017; 20(1):E183-E193. PubMed ID: 28072811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Codeine/acetaminophen and hydrocodone/acetaminophen combination tablets for the management of chronic cancer pain in adults: a 23-day, prospective, double-blind, randomized, parallel-group study.
    Rodriguez RF; Castillo JM; Del Pilar Castillo M; Nuñez PD; Rodriguez MF; Restrepo JM; Rodriguez JM; Ortiz Y; Angel AM
    Clin Ther; 2007 Apr; 29(4):581-7. PubMed ID: 17617281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Analysis of Rescue Medication Utilization from a 3-Month, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Chronic Low Back Pain Treated with Single-Entity, Twice-Daily, Extended-Release Hydrocodone.
    Nalamachu S; deLeon-Casasola OA; Robinson CY; Galer BS; Gould E; Gammaitoni A
    Pain Med; 2015 Dec; 16(12):2338-43. PubMed ID: 26301791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
    Hale ME; Ahdieh H; Ma T; Rauck R;
    J Pain; 2007 Feb; 8(2):175-84. PubMed ID: 17145204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH; Gould E
    Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analgesic efficacy and tolerability of oxycodone 5 mg/ibuprofen 400 mg compared with those of oxycodone 5 mg/acetaminophen 325 mg and hydrocodone 7.5 mg/acetaminophen 500 mg in patients with moderate to severe postoperative pain: a randomized, double-blind, placebo-controlled, single-dose, parallel-group study in a dental pain model.
    Litkowski LJ; Christensen SE; Adamson DN; Van Dyke T; Han SH; Newman KB
    Clin Ther; 2005 Apr; 27(4):418-29. PubMed ID: 15922815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.